EUROFINS SCIENT Share Holder Equity 2018-2024 | ERFSF
EUROFINS SCIENT share holder equity from 2018 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
- EUROFINS SCIENT share holder equity for the quarter ending December 31, 2024 was $5.827B, a 17.66% increase year-over-year.
- EUROFINS SCIENT share holder equity for 2024 was $5.827B, a 4.79% increase from 2023.
- EUROFINS SCIENT share holder equity for 2023 was $5.56B, a 8.79% increase from 2022.
- EUROFINS SCIENT share holder equity for 2022 was $5.111B, a 7.64% decline from 2021.
| EUROFINS SCIENT Annual Share Holder Equity (Millions of US $) |
|
|---|---|
| 2024 | $5,827 |
| 2023 | $5,560 |
| 2022 | $5,111 |
| 2021 | $5,534 |
| 2020 | $4,245 |
| 2019 | $3,246 |
| 2018 | $3,215 |
| 2017 | $2,805 |
| 2016 | $0 |
| 2015 | $0 |
| EUROFINS SCIENT Quarterly Share Holder Equity (Millions of US $) |
|
|---|---|
| 2024-12-31 | $5,827 |
| 2023-06-30 | $5,526 |
| 2022-12-31 | $5,111 |
| 2021-12-31 | $5,534 |
| 2021-06-30 | $4,952 |
| 2020-12-31 | $4,245 |
| 2020-06-30 | $3,827 |
| 2019-12-31 | $3,246 |
| 2019-06-30 | $3,079 |
| 2018-12-31 | $3,215 |
| 2018-06-30 | $3,044 |
| 2017-12-31 | $2,805 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.514B | $7.522B |
| Eurofins Scientific SE provides testing services. The company provides food and feed testing, bioanalytical, biopharma, pharma discovery, pharma early development, pharma central laboratory, biopharma product testing, genomic, agroscience, consumer product testing, forensic, environment testing and REACH services. It operates primarily in Benelux, France, Germany, North America, Nordic countries, the United Kingdom, Ireland and internationally. Eurofins Scientific SE is headquartered in Luxembourg. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $133.694B | 25.08 |
| Elevance Health (ELV) | United States | $90.401B | 11.66 |
| CVS Health (CVS) | United States | $78.570B | 9.77 |
| Cencora (COR) | United States | $56.472B | 19.65 |
| DiDi Global (DIDIY) | China | $22.450B | 34.07 |
| Natera (NTRA) | United States | $20.631B | 0.00 |
| BioMerieux (BMXMF) | France | $15.355B | 0.00 |
| Solventum (SOLV) | United States | $12.588B | 13.33 |
| CochLear (CHEOY) | Australia | $11.382B | 0.00 |
| Revvity (RVTY) | United States | $10.588B | 18.22 |
| ICON (ICLR) | Ireland | $10.225B | 9.51 |
| Viatris (VTRS) | United States | $9.953B | 3.42 |
| Doximity (DOCS) | United States | $9.475B | 44.13 |
| Avantor (AVTR) | United States | $8.552B | 12.43 |
| HealthEquity (HQY) | United States | $8.545B | 42.04 |
| Medpace Holdings (MEDP) | United States | $8.501B | 22.58 |
| Sonic Healthcare (SKHHY) | Australia | $8.263B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.630B | 12.99 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $4.137B | 38.29 |
| Bausch + Lomb (BLCO) | Canada | $3.955B | 23.31 |
| Sotera Health (SHC) | United States | $3.503B | 19.90 |
| Alignment Healthcare (ALHC) | United States | $3.033B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.905B | 37.78 |
| Concentras Parent (CON) | United States | $2.803B | 16.20 |
| Organon (OGN) | United States | $2.191B | 2.33 |
| Ardent Health Partners (ARDT) | United States | $2.137B | 9.11 |
| GeneDx Holdings (WGS) | United States | $1.934B | 74.48 |
| Premier (PINC) | United States | $1.899B | 14.41 |
| Progyny (PGNY) | United States | $1.816B | 39.98 |
| PACS (PACS) | United States | $1.506B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.354B | 27.07 |
| Pediatrix Medical (MD) | United States | $1.303B | 9.91 |
| Teladoc Health (TDOC) | United States | $1.223B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.037B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| Agilon Health (AGL) | United States | $0.973B | 0.00 |
| CareDx (CDNA) | United States | $0.949B | 14.83 |
| Nutex Health (NUTX) | United States | $0.941B | 14.21 |
| AMN Healthcare Services Inc (AMN) | United States | $0.846B | 7.92 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| Embecta (EMBC) | United States | $0.722B | 4.86 |
| InnovAge Holding (INNV) | United States | $0.554B | 0.00 |
| Enhabit (EHAB) | United States | $0.528B | 43.46 |
| Auna S.A (AUNA) | Luxembourg | $0.506B | 11.40 |
| LifeMD (LFMD) | United States | $0.489B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.467B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.403B | 0.00 |
| SBC Medicals (SBC) | United States | $0.360B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.204B | 0.00 |
| Oncology Institute (TOI) | United States | $0.202B | 0.00 |
| Beauty Health (SKIN) | United States | $0.195B | 0.00 |
| KindlyMD (KDLY) | United States | $0.137B | 0.00 |
| DocGo (DCGO) | United States | $0.131B | 21.33 |
| So-Young (SY) | China | $0.089B | 0.00 |
| OncoCyte (OCX) | United States | $0.088B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.072B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.063B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 0.00 |
| Biodesix (BDSX) | United States | $0.058B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.057B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.036B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.035B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| ModivCare (MODV) | United States | $0.013B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |